WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530959

CAS#: 1613437-66-3 (free base)

Description: KBP-7018 is a novel, tyrosine kinase-selective inhibitor with potent effects on three fibrotic kinases (c-KIT, PDGFR, and RET). It IC50 values are: c-KIT 10nM; RET 7.6 nM; PDGFR 25nM. KBP-7018 represents a novel multikinase inhibitor with differentiated activity, highly enhanced selectivity, and acceptable PK profiles that will enter phase I clinical trials.

Price and Availability




KBP-7018 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 530959
Name: KBP-7018
CAS#: 1613437-66-3 (free base)
Chemical Formula: C31H30N4O5
Exact Mass: 538.2216
Molecular Weight: 538.604
Elemental Analysis: C, 69.13; H, 5.61; N, 10.40; O, 14.85

Related CAS #: 1613437-67-4 (HCl)   1613437-66-3 (free base)    

Synonym: KBP-7018; KBP 7018; KBP7018.

IUPAC/Chemical Name: methyl (Z)-3-(((1-(2-morpholinoacetyl)indolin-5-yl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate


InChi Code: InChI=1S/C31H30N4O5/c1-39-31(38)22-7-9-24-25(18-22)33-30(37)28(24)29(20-5-3-2-4-6-20)32-23-8-10-26-21(17-23)11-12-35(26)27(36)19-34-13-15-40-16-14-34/h2-10,17-18,32H,11-16,19H2,1H3,(H,33,37)/b29-28-

SMILES Code: O=C(OC)C1=CC=C2C(NC(/C2=C(NC3=CC=C(N(C(CN4CCOCC4)=O)CC5)C5=C3)/C6=CC=CC=C6)=O)=C1

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

Additional Information

Idiopathic pulmonary fibrosis (IPF) is a serious and deadly disease for which treatment options are limited. The recent approval of antifibrosis agent nintedanib represents one of the first therapeutic approaches for the treatment of IPF.


1. Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis
Zhenhua Huang, Heran Li, Qian Zhang, Fangzheng Lu, Mei Hong, Zhigang Zhang, Xiaocui Guo, Yuanju Zhu, Sanming Li, and Hongzhuo Liu
Publication Date (Web): September 30, 2017 (Letter)
DOI: 10.1021/acsmedchemlett.7b00164

2: Huang Z, Li H, Zhang Q, Tan X, Lu F, Liu H, Li S. Characterization of
preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new
tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary
fibrosis. Drug Des Devel Ther. 2015 Aug 5;9:4319-28. doi: 10.2147/DDDT.S83055.
eCollection 2015. PubMed PMID: 26273193; PubMed Central PMCID: PMC4532346.